Oncotarget

Clinical Research Papers:

The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer

Fanrong Zhang, Lisha Ying, Jiaoyue Jin, Kaiyan Chen, Nan Zhang, Junzhou Wu, Yimin Zhang and Dan Su _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:8835-8842. https://doi.org/10.18632/oncotarget.13053

Metrics: PDF 1838 views  |   HTML 2237 views  |   ?  


Abstract

Fanrong Zhang1,2,*, Lisha Ying2,*, Jiaoyue Jin1,2, Kaiyan Chen2, Nan Zhang1,2, Junzhou Wu2, Yimin Zhang3 and Dan Su1,2

1 Department of Oncology, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, China

2 Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China

3 Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou, China

* These authors have contributed equally to this work

Correspondence to:

Dan Su, email:

Keywords: C-reactive protein; albumin; inflammation-based prognostic score; prediction; survival

Received: August 26, 2016 Accepted: October 28, 2016 Published: November 03, 2016

Abstract

Purpose: To investigate the association between C-reactive protein/albumin ratio (CAR), an inflammation-based prognostic score, and clinicopathological factors, as well as its association with long-term outcomes in patients with operable non-small cell lung cancer (NSCLC).

Methods: A total of 617 operable NSCLC patients were retrospectively evaluated and the data of preoperative serum CRP and serum albumin was collected. The correlation between the CAR and clinicopathological factors was analyzed using the chi-square test. A Cox proportional hazards regression model was performed to evaluate the association between the CAR and outcome.

Results: The CAR was significantly related to sex, smoking status, BMI, histology type and clinical stage (p ≤ 0.05). The patients with characteristic of male, smoker, BMI under 18.5, squamous cell carcinoma or clinical stage III had a high level of CAR. Additionally, elevated CAR indicated a worse outcome, and the patients with higher CAR had 2.02-fold risk for disease progression (95% CI 1.48-2.74, p < 0.001) and 2.61-fold risk for death (95 % CI 2.02-3.37, p < 0.001). Multivariate analyses showed the similar results after adjusted by clinicopathological factors and another four inflammation-based prognostic scores.

Conclusions: The CAR is a potential independent predictor for disease progression and death in patients with operable NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13053